Caris Life Sciences, Inc. (CAI)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. David Dean Halbert M.D.
|
Chairman, CEO & Founder | 4.95M | -- | 1956 |
|
Mr. Brian J. Brille J.D.
|
Executive Vice Chairman & Executive VP | -- | -- | 1961 |
|
Dr. David Spetzler M.B.A., M.S., Ph.D.
|
President | 1.33M | -- | 1977 |
|
Mr. J. Russel Denton
|
Senior VP, General Counsel & Secretary | 736.85k | -- | 1984 |
|
Mr. Luke Power
|
Senior VP, CFO & Chief Accounting Officer | -- | -- | 1982 |
|
Mr. Jon Mark Harmon
|
Senior VP & Chief Operations Officer | -- | -- | -- |
|
Dr. Milan Radovich Ph.D.
|
Senior VP & Chief Scientific Officer | -- | -- | -- |
|
Mr. Jeremy O'Brien
|
Senior VP of HR & Chief Compliance Officer | -- | -- | -- |
|
Mr. Narendra Chokshi
|
Senior Vice President of Corporate Development | -- | -- | -- |
|
Ms. Stephanie Thomas
|
Executive VP & Chief of Staff at Office of the CEO | -- | -- | -- |
Caris Life Sciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,846
Description
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Corporate Governance
Upcoming Events
November 4, 2026 at 9:00 PM UTC
Caris Life Sciences, Inc. Earnings Date
